Should the Multiple Sleep Latency Test be deferred in a patient taking duloxetine and lamotrigine?

Should You Defer MSLT in a Patient on Duloxetine and Lamotrigine?

Yes, you should defer the Multiple Sleep Latency Test (MSLT) and discontinue duloxetine at least 2 weeks prior to testing (6 weeks if on fluoxetine). Lamotrigine does not require discontinuation as it does not suppress REM sleep.

Why Duloxetine Must Be Discontinued

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that suppresses REM sleep and significantly alters MSLT results 1. The most compelling evidence comes from a 2020 study demonstrating that patients who discontinued REM-suppressing antidepressants (REMS-ADs) prior to MSLT had:

• 12-fold higher odds of having ≥2 sleep-onset REM periods (SOREMs) compared to those who remained on these medications 2
• Significantly shorter mean sleep latency (8.77 vs 10.21 minutes, p=0.009) 2
• 2.22 times higher odds of demonstrating ≥2 SOREMs compared to patients never on these medications 2

These differences persisted even after controlling for confounding variables, making this the strongest evidence that continuing duloxetine during MSLT produces false-negative results that could miss narcolepsy diagnoses 2.

Clinical Practice Guidelines Support Discontinuation

The 2008 AACAP clinical guideline explicitly states that polysomnography and daytime MSLT are not routinely indicated for insomnia evaluation, but when performed, medications affecting sleep architecture must be considered 3. While this guideline doesn't specifically address pre-test medication withdrawal, the 2011 wrist actigraphy guideline emphasizes that actigraphy should document sleep patterns prior to MSLT 4, implicitly supporting medication stabilization or withdrawal.

The standard protocol at major sleep centers (including Mayo Clinic) is to discontinue all antidepressants 2 weeks prior to MSLT 2. This has become the de facto standard of care based on the understanding that these medications fundamentally alter the test's validity.

Lamotrigine Does Not Require Discontinuation

Lamotrigine is an anticonvulsant/mood stabilizer that does not suppress REM sleep and is not listed among medications that interfere with MSLT interpretation 5. The evidence shows:

• No documented REM-suppressing effects
• Not classified as a REMS-AD in the systematic literature 2
• Can be safely continued during MSLT testing

One important caveat: A 2022 case report documented that lamotrigine can cause a false-positive PCP result on urine drug screens 6, but this is irrelevant to MSLT interpretation and sleep architecture.

Practical Implementation Algorithm

Step 1: Assess Clinical Urgency

• If narcolepsy or hypersomnia suspected: Proceed with medication taper
• If patient psychiatrically unstable: Defer MSLT until stable enough to safely withdraw duloxetine

Step 2: Duloxetine Discontinuation Protocol

• Taper over 2-4 weeks minimum to avoid discontinuation syndrome 7
• Common withdrawal symptoms include: dizziness, headache, nausea, paresthesia, irritability, insomnia, anxiety 7
• Complete discontinuation 2 weeks before MSLT 2
• Consider psychiatric consultation if patient has severe depression/anxiety

Step 3: Continue Lamotrigine

• No dose adjustment needed
• Monitor for combination therapy effects if duloxetine was being used with lamotrigine for bipolar depression 8

Step 4: Pre-MSLT Documentation

• Use actigraphy for 1-2 weeks prior to MSLT to document sleep-wake patterns 4
• Ensure adequate sleep duration (avoid sleep deprivation confounding)
• Document all remaining medications

Critical Warnings

If you proceed with MSLT while patient remains on duloxetine, you must:

1. Document in the interpretation that results may be falsely negative for narcolepsy
2. State that REM suppression from duloxetine may mask SOREMs
3. Consider the test non-diagnostic if clinical suspicion for narcolepsy remains high despite negative results
4. Plan for repeat testing after medication discontinuation if initial results are inconclusive

The FDA labeling for duloxetine notes adverse effects including insomnia, somnolence, dizziness, and orthostatic hypotension 7, all of which can independently affect sleep architecture and MSLT validity, providing additional rationale for discontinuation.

Bottom line: The evidence strongly supports deferring MSLT until duloxetine can be safely discontinued for at least 2 weeks. Lamotrigine can be continued. 2